Evidence map›Paper›PMID 38265381›Full record

ReviewAnti-cancer agents in medicinal chemistry2024

Potential of Nanomedicines as an Alternative for the Treatment of Colorectal Cancer - A Review.

Kammila Martins Nicolau Costa, Larissa Alves Barros, Ingrid Larissa da Silva Soares, João Augusto Oshiro-Junior

Abstract readReview
PubMed Publisher
In one paragraph

Review in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kammila Martins Nicolau CostaPost-graduation Program in Technological Development and Innovation in Medicines (PPgDITM) - Universidade Federal da Paraíba, João Pessoa, PB, Brazil.ORCID 0000-0003-2923-6036
Larissa Alves BarrosUNIFACISA - Campina Grande, PB, Brazil.
Ingrid Larissa da Silva SoaresUNIFACISA - Campina Grande, PB, Brazil.
João Augusto Oshiro-JuniorPost-graduation Program in Technological Development and Innovation in Medicines (PPgDITM) - Universidade Federal da Paraíba, João Pessoa, PB, Brazil.ORCID 0000-0001-7247-1598

Funding

Coordenação de Aperfeiçoamento Pessoal de Nível Superior, Brazil (CAPES) Finance Code 001
6 · The paper itself

Abstract

Colorectal cancer is the third most common cancer and the second in cases of cancer-related death. Polytherapy generates many adverse effects, leading the patient to give up. Nanotechnology has been studied in recent years to circumvent limitations. Groups composed of polymeric, lipid, and inorganic nanoparticles are the most purpose. Thus, the objective of this work is to bring information on how nanosystems can improve the chemotherapeutic treatment for colorectal cancer. Therefore, a search in journals such as "LILACS", "SciELO" and "PubMed/Medline" was performed, resulting in 25,000 articles found when applied the search engines "nanoparticle," "colorectal cancer," "malignant neoplasms," and "chemotherapy." After inclusion and exclusion factors, 24 articles remained, which were used as the basis for this integrative review. The results reveal that, regardless of the choice of matrix, nanoparticles showed an increase in bioavailability of the active, increasing the half-life by up to 13 times, modified release, as well as a significant reduction in tumor size, with cell viability up to 20% lower than the free drug tested, in different colorectal cancer cell lines, such as HCT-116, HT-29, and CaCo-2. However, more in vivo and clinical studies need to be performed, regardless of the formulation of its matrix, aiming at a higher rate of safety for patients and stability of the formulations, as well as knowledge of detailed indices of its pharmacokinetics and pharmacodynamics, seeking to avoid further damage to the recipient organism.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsNanomedicineNanoparticlesAnimalsCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansAntineoplastic Agents5-fluorouracilcancer treatmentchemotherapydrug delivery systemNanoparticlesresistance mechanisms.

Identifiers

PMID38265381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.